Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. (2019)
Attributed to:
Centre for Drug Safety Science (CDSS)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/jia2.25352
PubMed Identifier: 31298496
Publication URI: http://europepmc.org/abstract/MED/31298496
Type: Journal Article/Review
Volume: 22
Parent Publication: Journal of the International AIDS Society
Issue: 7
ISSN: 1758-2652